Issar Pharmaceuticals

since its inception, issar pharma has been working on development of new peptide based drugs to treat different health problems. after six years of committed research, issar pharma invented and commercialised india’s first ever indigenously developed new peptide molecule, decapeptide, for the novel treatment of vitiligo. this product was released into the market in 2004 under the product name melgain®. issar pharma also invented and developed for the first time in the world its second peptide new chemical entity (nce) which is first ever peptide based drug to treat burn wounds and microbial infection in india and world. this is going to be launched in indian market soon with the brand name of xylentra™. the other molecules in pipeline are intended to be active against cancer, diabetic ulcers, hiv-aids, acne, psoriasis, atopic dermatitis, inflammatory bowel disease, etc.